1
9
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39659 |
(S,R,S)-AHPC-CO-C9-acid
VH032-NH-CO-C9-acid,(S,R,S)-AHPC-CO-C9-acid |
Others | Others |
(S,R,S)-AHPC-CO-C9-acid is a ligand-linker conjugate specifically designed to function as an E3 ligase ligand. This compound possesses the capability to be attached to a ligand, which enables the formation of PROTACs with proteins. |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPJ-00865 |
VEGF121 Protein, Human, Recombinant (His)
VEGFA,VEGF-A,Vascular pe... |
Human | HEK293 Cells |
Human VEGF121, also known as Vascular endothelial growth factor A, VEGFA, Vascular permeability factor, VPF and VEGF, is a homodimeric, heparin-binding glycoprotein which belongs to the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family. VEGF-A is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis, permeabilization of blood vessel... | |||
TMPY-03698 |
VEGF121b Protein, Human, Recombinant
MVCD1,VEGF,VPF,vascula |
Human | HEK293 Cells |
VEGF121b Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 34.10 kDa and the accession number is P15692-9. | |||
TMPH-00005 |
YAP1 Protein, Human, Recombinant (Isoform 9, His)
Protein yorkie homolog,YAP1,Yes |
Human | P. pastoris (Yeast) |
YAP1 Protein, Human, Recombinant (Isoform 9, His) is expressed in yeast with C-6xHis tag. The predicted molecular weight is 56.4 kDa; 80 kDa, reducing conditions and the accession number is P46937-9. | |||
TMPK-00825 |
VEGF121 Protein, Human, Recombinant (His & Avi)
VPF,VEGF,VEGFA,VEGFMGC70609,血管内皮生长因子,MG |
Human | HEK293 Cells |
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. VEGF121 Protein, Human, Recombinant (His & Avi) is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 17 kDa and the accession number is P15692-9. | |||
TMPK-00826 |
VEGF121 Protein, Human, Recombinant (His & Avi), Biotinylated
VAS,VEGFMGC70609,R |
Human | HEK293 Cells |
Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF), is a potent mediator of both angiogenesis and vasculogenesis in the fetus and adult. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189. VEGF121 Protein, Human, Recombinant (His & Avi), Biotinylated is expressed in HEK293 mammalian cells with C-His-Avi tag. The predicted molecular weight is 17 kDa and the accession number is P15692-9. | |||
TMPY-05268 |
Neurofascin Protein, Human, Recombinant (hFc), Biotinylated
NRCAML,neurofas... |
Human | HEK293 Cells |
Neurofascin Protein, Human, Recombinant (hFc), Biotinylated is expressed in HEK293 mammalian cells with hFc tag. The predicted molecular weight is 130 kDa and the accession number is O94856-9. | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RA<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MH... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-<... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |